Narsoplimab not checked
Omeros Corporation · OMS721
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
- Main trialPhase 2
- “The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).”In the company’s words, NCT05855083 on ClinicalTrials.gov
- Other names
- OMS721
Other drugs for Thrombotic Microangiopathies
- RilzabrutinibSanofi · Phase 3
- Human immunoglobulinGrand Shuyang Life Sciences (Chengdu) Co., Ltd. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- TAK-755Takeda · Phase 3
- TQB3473Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Efgartigimodargenx · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2025 | Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA | |
| Phase 3Terminated | 2 Feb 2021 | Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome | |
| Phase 3Terminated | 12 Jan 2024 | Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy | |
| Phase 2Completed | 30 Jan 2020 | Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies | |
| Phase 2Terminated | 25 Aug 2020 | Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026